Marble Harbor Investment Counsel LLC Trims Position in Edwards Lifesciences Corporation $EW

Marble Harbor Investment Counsel LLC lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 4.8% in the second quarter, Holdings Channel.com reports. The firm owned 59,741 shares of the medical research company’s stock after selling 3,033 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Edwards Lifesciences were worth $4,672,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $266,000. Allworth Financial LP lifted its position in Edwards Lifesciences by 6.3% during the 1st quarter. Allworth Financial LP now owns 3,513 shares of the medical research company’s stock worth $264,000 after acquiring an additional 208 shares in the last quarter. Alps Advisors Inc. acquired a new position in shares of Edwards Lifesciences during the first quarter worth $369,000. CWM LLC boosted its position in Edwards Lifesciences by 36.3% in the 1st quarter. CWM LLC now owns 32,916 shares of the medical research company’s stock valued at $2,386,000 after buying an additional 8,772 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Edwards Lifesciences by 11.5% in the first quarter. Signaturefd LLC now owns 6,202 shares of the medical research company’s stock valued at $450,000 after purchasing an additional 638 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 1.3%

Edwards Lifesciences stock opened at $85.14 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $49.41 billion, a price-to-earnings ratio of 12.25, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a 50 day moving average price of $77.90 and a 200 day moving average price of $77.53.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 22,970 shares of company stock worth $1,862,878. 0.34% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Tuesday, July 29th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research report on Monday, November 3rd. Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.